STOCKSCREENR
Log In

NRIX

NASDAQ

Nurix Therapeutics, Inc.

$15.48+0.10(+0.65%)Mkt Cap: $1.34B

Key Stats

Market Cap

$1.34B

P/E Ratio

-5.08

EPS

$-3.05

Dividend Yield

0.00%

52-Week Range

$8.18 — $22.50

Volume

1.28M

Avg Volume

1.11M

Beta

2.02

Valuation

P/E (TTM)

-5.08

Forward P/E

—

PEG Ratio

2.43

P/S (TTM)

16.46

P/B (TTM)

2.82

P/FCF

—

EV/EBITDA

—

EV/Sales

—

Financial Health

ROE (TTM)

-0.58%

ROA (TTM)

-0.38%

ROIC

—

Gross Margin

-0.87%

Operating Margin

-3.40%

Net Margin

—

Debt/Equity

0.10

Current Ratio

7.02

Growth

EPS Growth (YoY)

—

Revenue Growth (YoY)

—

EPS Growth (3Y)

+0.05%

EPS Growth (5Y)

-0.04%

Sales Growth (3Y)

+0.41%

Sales Growth (5Y)

+0.44%

EPS Est (This Year)

$-3.14

EPS Est (Next Year)

$-2.99

Dividends

Dividend Yield

—

Annual Dividend

—

Payout Ratio

—

Frequency

—

Ex-Dividend Date

—

Cash/Share

$6.24

Analyst Consensus

Price Target Range

$28.00$30.00$36.00
LowMedianHigh

Consensus Target: $31.22(101.7% upside)

Ownership

Institutional %

—

Inst. Net Change

—

Insider Net Shares (90d)

—

Outstanding Shares

86.67M

Float

80.54M

Free Float %

92.93%

About

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

NASDAQ

IPO Date

2020-07-24

Employees

286

CEO

Arthur T. Sands

Index Membership

—

Website

https://www.nurixtx.com

Nurix Therapeutics, Inc. (NRIX) is a healthcare company in the biotechnology industry listed on the NASDAQ. With a market capitalization of $1.34B, a P/E ratio of -5.08, NRIX is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare NRIX against other stocks using dozens of fundamental and technical filters.

Similar Stocks

CYBN

Cybin Inc.

$8.28

+1.22%

$413.02M

FRX.TO

Fennec Pharmaceuticals Inc.

$10.72

-0.05%

$295.33M

BTX

BlackRock Technology and Private Equity Term Trust

$6.49

+1.56%

$757.45M

BHVN

Biohaven Ltd.

$9.53

-1.14%

$1.01B

VKTX

Viking Therapeutics, Inc.

$35.53

-1.33%

$4.11B

STOK

Stoke Therapeutics, Inc.

$32.87

-3.21%

$1.88B

Frequently Asked Questions

What is Nurix Therapeutics, Inc.'s P/E ratio?

Nurix Therapeutics, Inc. (NRIX) has a trailing twelve-month (TTM) P/E ratio of -5.08. This is below the market average, which may suggest the stock is undervalued or has lower growth expectations. The P/E ratio measures how much investors are willing to pay per dollar of earnings.

Does Nurix Therapeutics, Inc. pay a dividend?

No, Nurix Therapeutics, Inc. (NRIX) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.

What is Nurix Therapeutics, Inc.'s market cap?

Nurix Therapeutics, Inc. (NRIX) has a market capitalization of $1.34 billion, classifying it as a small-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.